Current IL-6 inhibitors in clinical trials for kidney disease mainly consist of TCZ, clazakizumab (an anti-IL-6R antibody), ziltivekimab (an IL-6 ligand inhibitor), and baricitinib (a JAK inhibitor). This evidence concerns the gene IL6 and kidney disorder.